Product information and disease descriptionProduct descriptionProduct information
Dosing and administration
3 evidence topics · 1 source
Lytenava (bevacizumab-vikg)
Neovascular age-related macular degeneration
- Manufacturer
- Outlook Therapeutics
- Regulatory submission
- BLA approved July 2026
- Last updated